Back to results
US 2025/0221990 A1Published application
Topical administration to the oral cavity
AssigneeCMPD Licensing, LLC
InventorJay Richard Ray, II
Life of this patent
Estimating the term…
Abstract
A method of treating erectile disfunction includes administering a pharmaceutically effective amount of a topical composition comprising an anhydrous suspension including tadalafil or vardenafil to an oral cavity of a subject for oral absorption therein. The topical composition is formulated to self-emulsify in an aqueous environment of the oral cavity.
Claims30
A topical composition for administration to an oral cavity of a subject and oral absorption therein to treat erectile disfunction, the topical composition comprising:
- an anhydrous suspension comprising:
- tadalafil or vardenafil,
- medium chain triglycerides,
- between 0.5% w/w and 10% w/w phosphatidylcholine,
- between 0.1% w/w and 1% w/w lysophosphatidylcholine,
- glyceryl distearate, and
- glyceryl monostearate,
- wherein the anhydrous suspension self-emulsifies in an aqueous environment of the oral cavity of the subject to form a mixed micelle and liposome delivery system for transmucosal delivery of the sumatriptan within the oral cavity.
5 more elements
A method of treating erectile disfunction, comprising:
- administering an anhydrous suspension to an oral cavity for oral absorption therein, the anhydrous suspension comprising:
- tadalafil or vardenafil,
- medium chain triglycerides,
- between 0.5% w/w and 10% w/w phosphatidylcholine,
- between 0.1% w/w and 1% w/w lysophosphatidylcholine,
- glyceryl distearate, and
- glyceryl monostearate,
- wherein the anhydrous suspension self-emulsifies in an aqueous environment of the oral cavity of the subject to form a mixed micelle and liposome delivery system for transmucosal delivery of the sumatriptan within the oral cavity.
5 more elements
Dependencies are inferred from the claim text.